55 results about "Calcium flux" patented technology

The present invention includes a group of chemical compounds useful as modulators of calcium ion (Ca2+) channels, especially for T-type, N-Type and L-type channels. The present invention also includes pharmaceutical compositions comprising these calcium ion channel modulating agents and methods of using these calcium ion channel modulating agents for the treatment diseases and conditions associated with the calcium ion channels.

Techniques are described for delivering inotropic electrical therapy to myocardial tissue using an implantable cardiac stimulation device such as a pacemaker. In one example, electrical stimulation is applied by a pacemaker to the heart of a patient while taking into account dynamic trans-cardiac impedance waveforms measured within the patient. In another example, a series of subthreshold inotropic stimulation pulses are delivered just prior to delivery of a suprathreshold depolarizing pulse that triggers systole. Additional subthreshold inotropic stimulation pulses can also be delivered following the suprathreshold pulse. Preferably, the magnitudes of the inotropic pulses are incrementally increased prior to systole then decremented thereafter, thereby gradually recruiting myocardium that has differing thresholds for depolarization. Both techniques seek to improve myocardial contractility of diseased tissue by improving calcium flux. Both techniques may additionally exploit the use of “multidimensional forced fusion”, described herein.

The present invention provides a method, system and composition for screening drug candidates for cardiotoxicity and for novel drugs that effect cardiomyocyte contractility and function. The invention provides an efficient and reliable screening assay to detect the effect of new and potential drug candidates on cardiomyocyte calcium flux, membrane depolarization, and / or the propagation of action potentials.

Aromatic derivatives of aliphatic diamines are effective in ameliorating conditions characterized by unwanted calcium ion channel activity, especially T-type and N-type channels. These conditions include, for example, stroke and pain.

The present invention pertains to methods to promote outgrowth of, or extension across a substrate of, neuronal cells by inhibiting the interaction between the cytoplasmic tail of the L1-CAM cell surface adhesion molecule and the cytoskeletal protein ankyrin. The invention also pertains to a method to treat diseases characterized by axonal damage such as spinal cord injury, traumatic brain injury, stroke, and neurodegenerative disease by administration of novel peptides that inhibit the binding of the L1-CAM cytoplasmic tail to ankyrin, and to pharmaceutical compositions comprising such peptides. The invention further pertains to a method of blocking calcium flux to protect against neural cell death following stroke or traumatic head injury.

The present invention includes a group of chemical compounds useful as modulators of calcium ion (Ca2+) channels, especially for T-type, N-Type and L-type channels. The present invention also includespharmaceutical compositions comprising these calcium ion channel modulating agents and methods of using these calcium ion channel modulating agents for the treatment diseases and conditions associated with the calcium ion channels.

The invention provides an application of 3-hydroxy fatty acid and derivatives thereof in the preparation of calcium ion channel regulator. An in vitro test indicates that the calcium ion channel regulator promotes neuroglia cell growth and activates cell calcium ion channel; and can be used for treating disease correlated to insufficient activation of the calcium ion channel, and used for culturing cell in vitro, particularly neuroglia cell.

The methods and systems described herein are based, in part, on the discovery that STIM modulates calcium release from store-operated channels through a direct interaction with the ORAI channel. Based on this discovery, methods and systems are described herein for identifying an agent that modulates calcium flux through the ORAI channel and / or regulates intracellular calcium via the ORAI channel. The methods and systems can also be used to detect an interaction between STIM and a functional ORAI channel.

The instrumentation and methods described herein are based on imaging and measuring single cell dose response by fluorescent ion imaging that records live cell responses to drug doses with no apparent damage to the cells or toxic side effects. Dose response curves and other pharmacological parameters can be computed by imaging and measuring oscillation changes for each dose and each cell. Large variability of cellular responses under the same experimental conditions indicates that pharmacological benchmarks are determined by statistical distribution of cells and cellular physiology. The instrumentation and methods described herein provide a means of measuring statistical variability of cell populations for improved screening and development methods for drugs.

The invention aims to extend application of a galangal extract which contains galangin and is used to inhibit the calcium channel, in particular TRP (Transient ReceptorPotential) channel, so as to prevent and treat heart cerebrovascular diseases such as atherosclerosis and the like. The TRP channel is a non-selective cation channel and has a close relation with heart cerebrovascular diseases such as atherosclerosis and the like. By inhibiting the activity of TRPC channel of vascular endothelial cells, the vascular function can be improved obviously and the vascular pathological changes of atherosclerosis can be improved obviously too. Chemical protection, antioxidation, antiviral and antibacterial action, anti-cancer effect of galangin are further explored previously and the invention extends the use of the galangal extract to prepare medicine for preventing and treating heart cerebrovascular diseases.

Disclosed are materials and methods for preparing optically active ss-amino acids of Formula (1), which bind to the alpha-2-delta (a2d) subunit of a calcium channel.

Assay methods for analyzing whole blood to detect histamine H4 receptor-mediated effects, such as eosinophil shape change, cytoskeletal change, adhesion molecule up-regulation, or calcium flux are described. Such methods are useful in clinical and diagnostic applications.

The present invention includes a group of chemical compounds useful as modulators of calcium ion (Ca2+) channels, especially for T-type, N-Type and L-type channels. The present invention also includes pharmaceutical compositions comprising these calcium ion channel modulating agents and methods of using these calcium ion channel modulating agents for the treatment diseases and conditions associated with the calcium ion channels.

A therapeutic composition for inhibiting physiological responses elicited by exposure of skin to an irritant can be used to treat exposure to capsaicinoids or other chemical irritants. The therapeutic composition can include a carrier being present in an effective amount and form sufficient to be applied to skin and deliver active agents to the skin which has been previously exposed to a capsaicinoid. Also, the therapeutic composition can include a cooling agent in an effective amount within the carrier to provide a cooling sensation to the skin. Further, the therapeutic composition can include a capsaicin receptor antagonist in an effective amount within the carrier to inhibit calcium flux associated with activation of the capsaicin receptor by a capsaicinoid. The therapeutic composition can be part of a kit that also includes a cleansing composition, which is capable of cleaning and / or absorbing capsaicinoids from the skin.

Provided are methods of treating various forms of hearing loss caused by aberrant calcium fluxes in auditory cells. The methods encompass the administration of agents which prevent abnormal calcium fluxes, stabilize SERCA2b activity, or prevent ER UPR apoptotic responses. The methods include therapeutic treatments of subjects suffering from hearing loss as well as preventative treatments which protect auditory cells from cell death, for example as caused by exposure to loud noise.

The invention relates to application of isoquercitrin as an inhibitor of a calcium ion channel, and belongs to the field of medicine. The invention also provides application of the isoquercitrin in preparation of drugs for treating cardiovascular diseases, coronary heart diseases, atherosclerosis, advanced renal failure, neurological diseases, chronic pain, acute pain or inflammatory diseases. Theinvention proves that the isoquercitrin can inhibit the calcium ion channel, especially a TRPC ion channel, and expands the application of the isoquercitrin.

The invention discloses application of Thonningianin A (TA) in preparation of a medicine serving as an L-type calcium ion channel activator. The medicine can be used for preventing or / and treating vascular calcification of human or animals. The application has the beneficial effects that penthorum chinense pursh extract TA has the effect of preventing and treating the diabetes-related vascular calcification diseases, the action mechanism of the penthorum chinense pursh extract TA is found, and the new application of the penthorum chinense pursh extract TA in preparation of the medicine serving as the cell membrane L-type calcium channel activator is provided; and TA-containing medicine has the application prospect of preventing or / and treating human or animal vascular calcification.

The invention discloses a method for preparing a manganese ferrite spinel material by utilizing a high-lead and high-phosphorus manganese resource, and an additive. The additive is prepared from an iron-containing substance, a calcium fluxing agent and sodium salt; the method for preparing the manganese ferrite spinel material by strengthening lead removal and phosphorus removal of the high-lead and high-phosphorus manganese resource through utilizing the additive comprises the following steps: after grinding the high-lead and high-phosphorus manganese resource, mixing the powder with the additive, agglomerating, drying and roasting; then carrying out ore grinding and magnetic separation on a roasted material to obtain the manganese ferrite spinel material and tailings containing rich leadand phosphorus. According to the method disclosed by the invention, harmful elements including the lead and the phosphorus in the high-lead and high-phosphorus manganese resource can be efficiently removed; meanwhile, the manganese ferrite spinel material is prepared; a ferromanganese spinel obtained by the magnetic separation has high purity and good magnetic performance; the method has the advantages of wide raw material sources, simple process, low cost and easiness for realizing industrial production.

The instrumentation and methods described herein are based on imaging and measuring single cell dose response by fluorescent ion imaging that records live cell responses to drug doses. Dose response curves and other pharmacological parameters can be computed by imaging and measuring oscillation changes for each drug dose and each cell. The instrumentation and methods described herein provide a means of measuring statistical variability of cell populations for improved screening and development methods for drugs.

The invention provides application of an abelmoschus manihot flower extract in preparation of a medicine for inhibiting calcium channels, belongs to the field of medicines, and further provides application of the abelmoschus manihot flower extract in preparation of medicines for treating cardiovascular diseases, coronary heart diseases, atherosclerosis, advanced renal failure, neurological diseases, chronic pain, acute pain or inflammatory diseases. The extract can selectively inhibit calcium ion channels, especially TRPC ion channels, so that the effects of different channels under physiological and pathophysiological conditions can be illustrated, a thought is developed for cardiovascular and cerebrovascular diseases, coronary heart diseases and other diseases, and the application of the abelmoschus manihot flower extract is expanded.

The invention relates to application of protocatechuic acid as an inhibitor of a calcium ion channel, and belongs to the field of medicine. The invention also discloses application of the protocatechuic acid in preparation of medicines for treating cardiovascular diseases, coronary heart diseases, atherosclerosis, advanced renal failure, neurological diseases, chronic pain, acute pain or inflammatory diseases, proves that the protocatechuic acid can inhibit the calcium ion channel, especially TRPC ion channel, and expands the application of the protocatechuic acid.

A method for tracking calcium flux of a eukaryotic cell. The method includes growing the eukaryotic cell in the presences of a ytterbium salt in solution and spectroscopically measuring ytterbium in the eukaryotic cell.

The invention discloses a method for improving the strength and the size composition of a sinter. The method is characterized in that when fluxes are added in a dosing chamber, a brucite fiber accounting for 0.90-0.95 % of the total mass of a sintered material is also added besides a calcium flux and a magnesium flux; after dosing, the brucite fiber, the calcium flux, the magnesium flux, an iron material and fuel are thoroughly mixed, and then water is added to wet the material to be subjected to a sintering process. Under the situation that the neutralized material structure, the fuel ratio and the sinter basicity remain unchanged, the brucite fiber is added, the sintering time is shortened from the original 24.2min to 21.9min, the productivity is increased by 26.6%, the sinter tumbler strength is improved by 9.15%, the average sinter size composition is improved by 2.25mm, the sinter solid fuel is decreased by 8.91kg / t, and the economic benefits are obvious, and the popularization and application values are great.

The invention discloses a method for removing lead from high-lead manganese resources. The method is to finely grind high-lead manganese resources, iron-containing materials and calcium flux respectively, then mix ore, mix and form agglomerates, and the obtained agglomerates are dried Finally, two stages of roasting are carried out to obtain roasted agglomerates; the roasted agglomerates are ground and magnetically separated to obtain magnetic iron concentrate and lead-rich tailings; the gangue content in the magnetic concentrate obtained by this method is low, especially The content of harmful element lead is extremely low, and it is a high-quality raw material for manganese alloys.

Two new conotoxin peptides ω-CPTx-btl1 and ω-CPTx-btl2 are provided, the amino acid sequences of which are shown in SEQ ID NO: 1 or 2 respectively, and polynucleotides encoding the two peptides are also provided , the construct, expression vector and transformed cell containing the polynucleotide and the preparation method of the two peptides, the conotoxin peptide can be used for the treatment of diseases related to calcium ion channels.

Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.

The invention relates to the technical field of pharmaceutical chemical synthesis, in particular to a triazole derivative capable of affecting calcium ion channels of tumor cells, a preparation method and application thereof. The present invention uses dolutegravir as a lead compound, utilizes the principle of drug splicing, and through a click reaction, changes the benzyl group in the dolutegravir structure into a 1,2,3-triazole structure to obtain a new compound, It can inhibit the growth of tumor cells by affecting calcium ion channels in tumor cells, and has significant application value.

The invention relates to the technical field of medicines, and relates to applications of 1-(6,7-dihydro-5H-furan-[3,2-g]chromene-3-acetyl)-4-phenylpiperazine (piperazine compound WY-42), pharmaceutically acceptable salts thereof, stereo-isomers thereof, pro-drugs thereof, and carries and diluents thereof acceptable in pharmaceutical formulation, in preparing medicines used for treating intestinal smooth muscle spasm diseases, and in gastrointestinal diseases as calcium ion channel antagonists. In animal in-vitro experiments, WY-42 can relax small intestine smooth muscle contraction caused by acetylcholine chloride, barium chloride, and potassium chloride. In a preliminary study of the relaxation mechanism of the compounds, it is found that, after an intestinal smooth muscle is incubated by using a calcium channel antagonist verapamil, the relaxation effect of WY-42 is inhibited. Therefore, the WY-42 can be used for preparing medicines used for treating intestinal smooth muscle spasm diseases, and can be used as a calcium ion channel antagonist.

The invention belongs to the field of pharmaceutical chemicals, and relates to a 3-(1-aryl-piperidin-4-yl)-2-aryl-thiazole-4-ketone compound, medicinal salt thereof, a preparation method thereof and use thereof, in particular to a compound shown in the formula I or medicinal salt thereof. The 3-(1-aryl-piperidin-4-yl)-2-aryl-thiazole-4-ketone compound or the medicinal salt thereof has obvious N-type calcium channel blocking-up activity and good pharmacokinetics properties, can prevent and cure or relieve pain effectively, and has potential used as novel medicine for preventing and / or treating pain, apoplexy and cerebral ischemia, alcohol addiction and intoxication, acute and chronic renal failure, or renal insufficiency.